Seborrheic Dermatitis

Inflammatory ICD: L21

Also known as: Seborrhoeic Eczema, Dandruff, Cradle Cap (infantile)

Description

Seborrheic dermatitis is a common chronic relapsing inflammatory condition affecting sebum-rich areas of the skin. It is mediated by Malassezia yeast and characterised by erythematous patches with greasy yellowish scales. Dandruff is considered a mild non-inflammatory variant limited to the scalp.

Symptoms

  • Erythematous patches with greasy yellow-white scales
  • Scalp flaking (dandruff) with pruritus
  • Nasolabial folds, eyebrows, behind ears affected
  • Blepharitis (eyelid involvement)
  • Chest and intertriginous areas in extensive cases

Causes & Triggers

  • Malassezia yeast overgrowth and inflammatory response to its metabolites
  • Sebaceous gland activity (lipid-rich environment)
  • Immune dysregulation (more severe in immunocompromised)
  • Neurological association (Parkinson's disease)
  • Stress, fatigue, and seasonal flares (winter)

Severity Classification

Mild Scalp flaking (dandruff) with minimal erythema
Moderate Facial and scalp involvement with visible scales and erythema
Severe Widespread facial, scalp, and truncal involvement

Treatment Ladder

  1. 1 Mild scalp: Antifungal shampoo (ketoconazole 2%, zinc pyrithione)
  2. 2 Face: Low-potency topical corticosteroids or topical antifungals
  3. 3 Moderate: Combination antifungal + anti-inflammatory
  4. 4 Maintenance: Intermittent antifungal shampoo or cream 1–2× per week
  5. 5 Severe / Refractory: Oral antifungal (itraconazole) short course

Relevant Compounds

Recommended Drugs

Suggested Cosmetics

Lifestyle Tips

  • Use medicated shampoos 2–3× per week, leaving on for 5 minutes before rinsing
  • Alternate between different antifungal shampoos to prevent resistance
  • Avoid heavy oily hair products
  • Manage stress — flares correlate with stress levels
  • Continue maintenance therapy even during remission periods

When to Refer

  • Resistant to standard topical therapy
  • Widespread or atypical distribution
  • Immunocompromised patients with severe disease
  • Diagnostic uncertainty (psoriasis, tinea, lupus overlap)